Daily Medication Pearl: Dapagliflozin (Farxiga) for Type 2 Diabetes Mellitus
By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose.
Medication Pearl of the Day: Dapagliflozin (Farxiga)
Indication: Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Dosing: The recommended starting dose is 5 mg once daily, taken in the morning, with or without food.
- Dosage form: Tablets 5 mg and 10 mg.
- Adverse events (AEs): The most common AEs associated with dapagliflozin(5% or greater incidence) were female genital mycotic infections, nasopharyngitis, and urinary tract infections.
- Mechanism of action: Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose, lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
- Manufacturer: AstraZeneca